Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-02-20
2007-02-20
Shibuya, Mark L. (Department: 1639)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024500, C435S006120
Reexamination Certificate
active
10120815
ABSTRACT:
A random combinatorial selection method is disclosed for the construction of oligonucleotide aptamers in which nuclease resistance is conferred by the inclusion of modified nucleotides. The modified nucleotides are incorporated during PCR amplification to form achiral modified oligonucleotides. Thio-substituted aptamers are provided that bind tightly to the nuclear factor for human IL6 (NF-IL6).
REFERENCES:
patent: 5218088 (1993-06-01), Gorenstein et al.
patent: 5397698 (1995-03-01), Goodman et al.
patent: 5470824 (1995-11-01), Miles et al.
patent: 5576302 (1996-11-01), Cook et al.
patent: 5587361 (1996-12-01), Cook et al.
patent: 5599797 (1997-02-01), Cook et al.
patent: 5602000 (1997-02-01), Hyman
patent: 5607691 (1997-03-01), Hale et al.
patent: 5607923 (1997-03-01), Cook et al.
patent: 5620963 (1997-04-01), Cook et al.
patent: 5635488 (1997-06-01), Cook et al.
patent: 5639873 (1997-06-01), Barascut et al.
patent: 5660985 (1997-08-01), Kirschenheuter et al.
patent: 5661134 (1997-08-01), Cook et al.
patent: 5705337 (1998-01-01), Gold et al.
patent: 5734041 (1998-03-01), Just et al.
patent: 5763595 (1998-06-01), Gold et al.
patent: 5795721 (1998-08-01), Rabin
patent: 5804445 (1998-09-01), Brasier
patent: 5853984 (1998-12-01), Davis
patent: 5874219 (1999-02-01), Rava et al.
patent: 6207646 (2001-03-01), Krieg et al.
patent: 6242246 (2001-06-01), Gold
patent: 6423493 (2002-07-01), Gorenstein
patent: 6458543 (2002-10-01), Gold
patent: 6503715 (2003-01-01), Gold
patent: 6544776 (2003-04-01), Gold
patent: 6867289 (2005-03-01), Gorenstein et al.
patent: 2003/0162216 (2003-08-01), Gold
patent: 2005/0214772 (2005-09-01), Gorenstein et al.
patent: WO 92 14842 (1992-09-01), None
patent: WO 92 14843 (1992-09-01), None
patent: WO 93 08296 (1993-04-01), None
patent: WO 96 19572 (1996-06-01), None
patent: WO 96 41019 (1996-12-01), None
patent: WO 99 31275 (1999-06-01), None
patent: WO 00 47774 (2000-08-01), None
Uhlmann et al., Aug. 1997, Studies on the mechanism of stabilization of partially phosphorothioated oligonucleotides against nucleolytic degradation, Antisense & Nucleic Acid Drug Development, vol. 7, pp. 345-350.
Tsukada et al., Nov. 1994, Transcriptional factors NF-IL6 and CREB recognize a common essential site in the human prointerleukin 1 beta gene, Molecular and Cellular Biology, vol. 14, No. 11, pp. 7285-7297.
Bielinska A et al: “Regulation of Gene Expression With Double-Stranded Phosphorothioate Oligonucleotides” Science, American Association for the Advancement of Science,, US, vol. 250, Nov. 16, 1990, pp. 997-1000, XP002065516 ISSN: 0036-8075.
Kunsch, Charles et al : “Selection of optimal.kappa.B/Rel DNA-binding motifs: interaction of bot subunits of NF-.kappa. B with DNA is required for transcriptional activation” Molecular and Cellular Biology ( 1992 ), 12(10), 4412 -2, XP009003474.
Antsypovich, Sergei et al: “Cross-linked DNA duplexes. Exonuclease stability and interactio with the nucleic transcription factor of the kappa. light-chai enhancer (NF-. kappa. B )” European Journal of Biochemistry (1998), 255(2), 414-421, XP002226148.
Sharma, H.W. et al.: “Transcription factor decoy approach to decipher the role of NF-KB in oncogenesis” Anticancer Research, vol. 16, 1996, pp. 61-70, XP009003192.
Morishita, R.M. et al.: “In vivo transfection of cis element “decoy” against nuclear factor-kB binding site prevents myocardial infarction” Nature Medicine, vol. 3, No. 8, 1997, pp. 894-899, XP009003193.
Khaled, Annette R. et al: “Use of phosphorothiate -modified oligodeoxynucleotides to inhibit NF-.kappa. B expression and lymphocyte function” Clinical Immunology and Immunopathology (1998), 86(2), 170-179, XP009003515.
Stec, W.J. et al.: “Deoxyribonucleoside 3′-O-(2-thio- and 2-oxo-“sprio”-4,4-pentamethylene-1,3,2-oxa thiaphospholane)s” J. Am.Chem. Soc., vol. 120, 1998, pp. 7156-7167, XP002239290.
Uhlmann E et al: “Stuudies on the Mechanism of Stabilization of Partially Phosphorothioated Oligonucleotides Against Nucleolytic Degradation” Antisense & Nucleic Acid Drug Development, Mary Ann Liebert, Inc., New York, US, vol. 7, No. 4, Aug. 1997, pp. 345-350, XP001117604 ISSN: 1087-2906.
Nakamaye, Kay L. et al: “Direct sequencing of polymerase chain reaction amplified DNA fragments through the incorporation of deoxynucleoside.alpha.—thiotriphosphates” Nucleic Acids Research (1988), 16(21), 9947-59, 1988, XP001097564.
King, et al., (1998) Novel Combinatorial Selection of Phosphorothioate Oligonucleotide Aptamers.Biochemistry, 37, 16489-16493.
Lebruska, et al. (1999) Selection and Characterization of an RNA Decoy for Transcription Factor NF-kB+,Biochemistry, 38, 3168-3174.
Zon, Gerald (1988) Oligonucleotide Analogues as Potential Chemotherapeutic Agents. Pharmaceutical Research, vol. 5, No. 9, pp. 539-549.
Brasier Allan R.
Gorenstein David G.
King David J.
Ventura Daniel A.
Board of Regents , The University of Texas System
Chalker Daniel J.
Chalker Flores LLP
Flores Edwin S.
Shibuya Mark L.
LandOfFree
Combinatorial selection of oligonucleotide aptamers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Combinatorial selection of oligonucleotide aptamers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combinatorial selection of oligonucleotide aptamers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3889468